Patents by Inventor Eisuke Tsuda
Eisuke Tsuda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10723800Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.Type: GrantFiled: May 25, 2012Date of Patent: July 28, 2020Assignee: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda
-
Publication number: 20200115446Abstract: An object of the present invention is to provide a pharmaceutical agent for the treatment and/or prophylaxis of pediatric osteoporosis without causing bone growth disorder in a subject to be medicated. A pharmaceutical composition for the treatment and/or prophylaxis of pediatric osteoporosis contains an antibody or a functional fragment thereof which binds to Siglec-15 and has activity of suppressing formation of osteoclasts and/or bone resorption by osteoclasts.Type: ApplicationFiled: June 29, 2018Publication date: April 16, 2020Applicants: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITEDInventors: Masahiko TAKAHATA, Dai SATO, Masahiro OTA, Tomohiro SHIMIZU, Chie FUKUDA, Eisuke TSUDA
-
Patent number: 10308715Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.Type: GrantFiled: October 11, 2017Date of Patent: June 4, 2019Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Yoshiharu Hiruma, Eisuke Tsuda
-
Patent number: 9815899Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.Type: GrantFiled: August 14, 2015Date of Patent: November 14, 2017Assignee: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda
-
Patent number: 9751944Abstract: Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: GrantFiled: June 5, 2015Date of Patent: September 5, 2017Assignee: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda, Takeshi Takizawa, Makiko Nakayama
-
Publication number: 20150344578Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.Type: ApplicationFiled: August 14, 2015Publication date: December 3, 2015Applicant: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda
-
Publication number: 20150299318Abstract: Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: ApplicationFiled: June 5, 2015Publication date: October 22, 2015Applicant: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda, Takeshi Takizawa, Makiko Nakayama
-
Patent number: 9114131Abstract: An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.Type: GrantFiled: October 4, 2011Date of Patent: August 25, 2015Assignee: Daiichi Sankyo Company, LimitedInventors: Ichiro Watanabe, Yoshiharu Hiruma, Eisuke Tsuda, Tatsuji Matsuoka, Toshiaki Ohtsuka, Tohru Takahashi, Toshinori Agatsuma, Sandra Miller, Robert Mühlbacher, Kathrin-Ladetzki Baehs, Steffen Runz, Ulrike Schubert, Ingrid Schuster, Dirk Ponsel
-
Patent number: 9090692Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.Type: GrantFiled: April 27, 2012Date of Patent: July 28, 2015Assignee: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda
-
Patent number: 9079959Abstract: Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: GrantFiled: September 30, 2013Date of Patent: July 14, 2015Assignee: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda, Takeshi Takizawa, Makiko Nakayama
-
Publication number: 20140065146Abstract: Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: ApplicationFiled: September 30, 2013Publication date: March 6, 2014Applicant: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda, Takeshi Takizawa, Makiko Nakayama
-
Patent number: 8575316Abstract: Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: GrantFiled: April 7, 2010Date of Patent: November 5, 2013Assignee: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda, Takeshi Takizawa, Makiko Nakayama
-
Publication number: 20130280276Abstract: An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.Type: ApplicationFiled: October 4, 2011Publication date: October 24, 2013Inventors: Ichiro Watanabe, Yoshiharu Hiruma, Eisuke Tsuda, Tatsuji Matsuoka, Toshiaki Ohtsuka, Tohru Takahashi, Toshinori Agatsuma, Sandra Miller, Robert Mühlbacher, Kathrin-Ladetzki Baehs, Steffen Runz, Ulrike Schubert, Ingrid Schuster, Dirk Ponsel
-
Patent number: 8546540Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.Type: GrantFiled: October 8, 2008Date of Patent: October 1, 2013Assignee: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda
-
Publication number: 20120329671Abstract: Novel proteins and polypeptides binding to osteoclastogenesis inhibitory factor (OCIF) (OCIF-binding molecules, OBMs) and nucleic acids encoding these proteins and polypeptides are provided. Processes for producing these proteins, polypeptides, and nucleic acid molecules by genetic engineering are provided. Medicinal compounds are provided which comprise proteins and nucleic acids according to the invention, as well as proteins which bind to OBM, including anti-OBM antibodies. These compounds may be used for the treatment of bone disease.Type: ApplicationFiled: August 16, 2012Publication date: December 27, 2012Applicant: AMGEN INC.Inventors: Kyoji Yamaguchi, Hisataka Yasuda, Nobuaki Nakagawa, Nobuyuki Shima, Masahiko Kinosaki, Eisuke Tsuda, Masaaki Goto, Kazuki Yano, Akihiro Tomoyasu, Fumie Kobayashi, Naohiro Washida, Ken Takahashi, Tomonori Morinaga, Kanji Higashio
-
Publication number: 20120251485Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.Type: ApplicationFiled: April 27, 2012Publication date: October 4, 2012Inventors: Yoshiharu Hiruma, Eisuke Tsuda
-
Publication number: 20120230988Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.Type: ApplicationFiled: May 25, 2012Publication date: September 13, 2012Inventors: Yoshiharu Hiruma, Eisuke Tsuda
-
Publication number: 20110268733Abstract: Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: ApplicationFiled: April 7, 2010Publication date: November 3, 2011Inventors: Yoshiharu Hiruma, Eisuke Tsuda, Takeshi Takizawa, Makiko NaKayama
-
Publication number: 20100209428Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.Type: ApplicationFiled: October 8, 2008Publication date: August 19, 2010Inventors: Yoshiharu Hiruma, Eisuke Tsuda
-
Publication number: 20100136011Abstract: Novel proteins and polypeptides binding to osteoclastogenesis inhibitory factor (OCIF) (OCIF-binding molecules, OBMs) and nucleic acids encoding these proteins and polypeptides are provided. Processes for producing these proteins, polypeptides, and nucleic acid molecules by genetic engineering are provided. Medicinal compounds are provided which comprise proteins and nucleic acids according to the invention, as well as proteins which bind to OBM, including anti-OBM antibodies. These compounds may be used for the treatment of bone disease.Type: ApplicationFiled: December 19, 2008Publication date: June 3, 2010Applicant: Daiichi Sankyo Company, LimitedInventors: Kyoji Yamaguchi, Hisataka Yasuda, Nobuaki Nakagawa, Nobuyuki Shima, Masahiko Kinosaki, Eisuke Tsuda, Masaaki Goto, Kazuki Yano, Akihiro Tomoyasu, Fumie Kobayashi, Naohiro Washida, Ken Takahashi, Tomonori Morinaga, Kanji Higashio